Authors



Ashwatha Narayana, MD

Latest:

Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation

ABSTRACT Symptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited survival and poor patient performance in that setting. In the era of targeted and personalized therapies, many patients are living longer and more functionally and are able to manage their disease on the model of chronic illness. Given these developments, an attractive option is the use of stereotactic body radiation therapy (SBRT) to deliver high biologically effective doses of radiation conformally to maximize the palliative gains of treatment. However, randomized data to guide practice are scarce. We review the extant literature and present an algorithmic approach to selecting patients with metastatic disease for palliative spinal SBRT favoring the results of available randomized studies and remaining within the safety constraints supported by evidence from randomized trials.


Bronson Riley, MS

Latest:

A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer

This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.



Kirsten Jorgensen, MD

Latest:

Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian Cancer

Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.


Khaled W. Kabbara, MD

Latest:

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy

Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.


Grzegorz Ziółkowski, MD

Latest:

Extreme Case of Surgical Port Metastasis in Ovarian Cancer

We present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.




David Morris, MD, MS

Latest:

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.


Kristin A. Higgins, MD

Latest:

Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and Future

McCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.




Moshe Ornstein, MD, MA

Latest:

Best Treatment Selection in Clear-Cell RCC

Medical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.


Usama Gergis, MD, MBA

Latest:

Potential Solutions to Disparities in Stem Cell Transplant for Blood Cancer

Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.


Yi Lin, MD, PhD

Latest:

Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.




Ben Kong, PharmD, BCPS

Latest:

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.







Christina Wu, MD

Latest:

Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer

Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.


Natalie A. Lockney, MD

Latest:

Advancing Pancreatic Cancer Care Through Intraoperative Radiation Therapy

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.


Christina S. Wu, MB, BCh, MD

Latest:

Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC

The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.


Rajat Thawani, MBBS

Latest:

Face-Off: Award Presentation Ceremony

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.


Zizhen Feng, MD

Latest:

Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.